Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

UFS receives record number of applications
2011-12-31

The University of the Free State (UFS) is looking forward to the start of the new academic year in January 2012, when thousands of new students will be joining the Kovsie family.

The UFS received almost 13 000 applications for studies in 2012. This is an increase of about 80% compared to the total number of applications received in 2010 for studies in 2011.

This increase is partly attributed to the university’s new method in approaching prospective students and the marketing initiatives followed during 2011. These included visits to various schools in the country by the Vice-Chancellor and Rector, Prof. Jonathan Jansen.

“This shows that the UFS is becoming a preferred place of study. Unfortunately, we can only take in about 4 000 first-years from these applications. We will, of course, choose the best and most diverse class of students,” says Prof. Jansen.

The university’s marketing initiatives will be intensified next year where students will take part as ambassadors in the university’s student recruitment campaigns for 2013.

Mr.Rudi Buys, The Dean of Student Affairs at the UFS, says Prof. Jansen’s visit to various schools in the country was very successful. This will be continued in 2012 and student leaders from residences, associations as well as the Student Representative Council will accompany him on these visits during the course of the year.

“These learners, just like our students, are part of a new generation of new democratic South Africans. Our students are excellent examples of youth leadership in the country and we are very excited about all our initiatives,” Mr Buys said.

The UFS is aware of the fact that learners will only receive their final Grade 12 results in January 2012. Final admission will therefore only be granted upon the submission of a certified copy of the matriculation results. Fax these results to 086 586 8947 or e-mail to applications@ufs.ac.za  as soon as it is available.

Important dates for Bloemfontein students

  • Friday and Saturday 13 & 14 January 2012: Welcoming of new first-years
  • Sunday 15 January: Gateway College life programme (Bloemfontein edition) begins)
  • Monday 16 January 2012: Registration starts 

Important dates for Qwaqwa students

  • Thursday 12 January 2012: Arrival of first-years
  • Friday 13 January 2012: Gateway College Life programme (Qwaqwa edition) begins.
  • Monday 16 January 2012: Registration starts

For more information, Bloemfontein students can contact Student Affairs at 051 401 9102 or send an e-mail to Cornelia Faasen at faasenc@ufs.ac.za . Qwaqwa students can contact Dulcie Malimabe at 058 718 5018 or send an e-mail to malimabedp@qwa.ufs.ac.za  

Media Release
Issued by:
Lacea Loader
Director: Strategic Communication
Telephone: +27 (0) 51 401 2584
+27 (0) 83 645 2454
E-mail: news@ufs.ac.za
Fax: +27 (0) 51 444 6393
Web: www.ufs.ac.za
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept